Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Combinature Biopharm (NMR Fragment-Based Drug Discovery Business)

M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of drug discovery platform created to discover novel enzymes and the respective genes. The company's genomics and robotics driven drug discovery platform is marketed for biocatalysis applications and, in parallel, used in-house in a high throughput combinatorial biosynthesis program, enabling customers and the company's NMR-aided drug discovery program a reach to library of essential natural compounds.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Primary Office
  • Robert-Rössle-Strasse 10
  • 13125 Berlin
  • Germany

Combinature Biopharm (NMR Fragment-Based Drug Discovery Business) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Combinature Biopharm (NMR Fragment-Based Drug Discovery Business)‘s full profile, request access.

Request full access to PitchBook

Combinature Biopharm (NMR Fragment-Based Drug Discovery Business) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Combinature Biopharm (NMR Fragment-Based Drug Discovery Business)‘s full profile, request access.

Request full access to PitchBook